Switzerland
· Delayed Price · Currency is CHF Basilea Pharmaceutica AG Company Description
Basilea Pharmaceutica AG engages in the discovering, developing, and commercializing drugs for bacterial or fungal infections.
The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis.
It also develops Fosmanogepix, an antifungal drug for the treatment of Candidemia, which is in Phase II clinical trials; BAL2062 for invasive mold infections, which is in Phase I of clinical trials; and BAL2420, an antibiotics to treat severe Enterobacteriaceae infections.
In addition, the company provides Zevtera, an antibiotic for the treatment of pneumonia, as well as develop for the treatment of Staphylococcus aureus bacteremia, acute bacterial skin, and skin structure infections.
Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.
| Country | Switzerland |
| Founded | 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 164 |
| CEO | David Veitch |
Contact Details
Address: Hegenheimermattweg 167b Allschwil, 4123 Switzerland | |
| Phone | 41 61 606 11 11 |
| Website | basilea.com |
Stock Details
| Ticker Symbol | BSLN |
| Exchange | SIX Swiss Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CHF |
| ISIN Number | CH0011432447 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| David Veitch | Chief Executive Officer |
| Adesh Kaul | Chief Financial Officer |
| Dr. Gerrit Hauck Ph.D. | Chief Technology Officer |
| Dr. Laurenz Kellenberger Ph.D. | Chief Scientific Officer |
| Dr. Marc Engelhardt M.D. | Chief Medical Officer |
| Dr. Peer Nils Schroder Ph.D. | Head of Corporate Communications and Investor Relations |
| Damian Heller | General Counsel and Corporate Secretary |
| Andreas Kumin | Head of Corporate Development |
| Ursula Eberhardt | Head of Global Human Resources |
| Mark Jones Ph.D. | Head of Global Affairs |